INTRODUCTION
Vitamin D is an essential nutrient that is often deficient in end-stage renal disease (ESRD) patients, primarily due to insufficient sunlight exposure, low dietary intake and loss of renal function. As a result, 78%-91% of ESRD patients are vitamin D deficient or insufficient at the time of dialysis initiation (1, 2) .
While vitamin D is critical to maintaining calcium and phosphorus homeostasis for optimal skeletal health, it also appears to play a significant role in vascular homeostasis. Circulating vitamin D [25(OH)D] is converted to 1,25(OH) 2 D in local tissues by the enzyme 1-alphahydroxylase. This further upregulates the vitamin D receptor (VDR) found in many tissues, including vascular smooth DOI: 10.5301/jva.5000187 Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study hyperplasia and to affect expression of oxidative and inflammatory markers detected within failing arteriovenous (AV) access (25) (26) (27) , we hypothesized that nutritional vitamin D supplementation (25(OH)D) may improve arteriovenous fistula (AVF) outcomes by providing adequate substrate to enable local, active vitamin D production within the vasculature.
We therefore conducted a double-blind, randomized, controlled pilot study to provide critical estimates to determine the distribution of vitamin D levels in our ESRD patient cohort in those who receive high-dose oral vitamin D3 (cholecalciferol) compared to placebo for the planning of subsequent, larger studies examining the effect of vitamin D on AVF maturation and to show feasibility for patient recruitment in the proposed time frame.
MATERIALS AND METHODS

Subjects and protocol
The protocol for this double-blind, randomized, placebo-controlled pilot study has been previously described (28) . Briefly, we enrolled 52 adults with ESRD receiving in-center outpatient hemodialysis who were preparing to receive an AVF creation within 4 weeks. Suitability of a patient for AVF creation was based on vein diameter >2.5 mm and inflow artery diameter >2 mm (29) . Enrolled subjects were randomized to 200,000 IU oral vitamin D3 (cholecalciferol) or matching placebo (Bio-Tech Pharmacal Inc, Fayetteville, AR, USA) weekly for 3 weeks. In a recent publication, we reported that our dosing regimen of high-dose cholecalciferol versus placebo is safe and effectively increases circulating serum 25(OH)D concentrations to the normal range of >30 ng/mL, lowers serum parathyroid hormone (PTH) concentration and does not cause hypercalcemia (28) . The study coordinator directly observed all patients taking their assigned medication, and there was 100% overall medication compliance. A blood sample was collected at study enrollment and again 3 weeks following study drug completion for measurement of serum 25(OH)D and 1,25(OH) 2 D. Monthly dialysis unit laboratory test results collected ≤4 weeks prior to study enrollment date and ≤4 weeks after study completion were abstracted to include in the analysis. The Emory University Institutional Review Board approved the study protocol, and all participants provided informed consent prior to study enrollment. The study was registered at clinicaltrials.gov (NCT00912782).
Outcome definition
The primary study outcome was mean response to high-dose oral vitamin D3 (cholecalciferol) versus placebo.
The secondary study outcome was AVF maturation, defined as the ability to cannulate the AVF with two large-bore needles at ≥6 consecutive dialysis sessions and achievement of an AVF blood flow >300 mL/min, assessed at 6 months following AVF creation.
Analytic methods
Serum 25(OH)D was assayed by using a chemiluminescence immunoassay (Diasorin Inc: CV over multiple runs: 6.3%-12.9%), and 1,25(OH) 2 D was assayed by using solid-phase extraction and radioimmunoassay by ARUP laboratories. All samples were batched and analyzed with known standards to ensure test quality. Vitamin D deficiency was defined as 20 ng/mL, and insufficiency was defined as 20-30 ng/mL. Levels to define vitamin D status were derived from The Endocrine Society clinical practice guidelines for vitamin D (30) because the Institute of Medicine guidelines are intended for a normal healthy population, not those with chronic disease.
Statistical analysis
Baseline characteristics and posttreatment blood chemistry measures including serum 25(OH)D concentration were compared between the placebo group and the cholecalciferol group using Wilcoxon rank sum tests for continuous variables and Fisher exact tests for categorical variables. Wilcoxon signed rank tests were used to test whether changes of blood chemistry measures from baseline to posttreatment were different from 0. AVF or arteriovenous graft (AVG) maturation status was compared between the two study groups using Fisher exact tests. Logistic regression analysis was performed to test the association between AVF/AVG maturation status and baseline and posttreatment vitamin D concentration and between AVF/AVG maturation status and changes in vitamin D concentration from baseline to posttreatment, first unadjusted and then adjusted for age, diabetes and race. The analyses were performed on an intention-to-treat basis using the free programming language and software environment for statistical computing, R. A p value of ≤0.05 was considered statistically significant.
RESULTS
A total of 52 subjects were enrolled: 25 were randomly assigned to the cholecalciferol treatment group, and 27 to receive placebo, as previously reported (28) . During follow-up, one subject was lost to follow-up, three died and four never received a permanent vascular access. Of these eight subjects, five were in the vitamin D group and three were in the placebo group. Characteristics of these Vitamin D and dialysis access maturation eight patients were similar to the remaining patient cohort, except for female gender (p=0.04). Overall, 44 subjects (24 in the placebo group; 20 in the cholecalciferol group) remained for analysis ( Fig. 1 ).
Clinical and laboratory characteristics
Clinical and laboratory characteristics were similar in the groups at baseline ( significantly increased in cholecalciferol-treated patients (p<0.001). There was no significant change in serum calcium, phosphorus or intact PTH.
AV access outcome
Overall, 15 radial-cephalic, 13 brachial-cephalic, 7 brachial-basilic AVFs were created and 9 AVGs surgically placed. At follow-up, 45% of cholecalciferol-treated and 54% of placebo-treated patients were successfully using their AVF or AVG at 6 months (p=0.8). Excluding AVG patients, 41% of cholecalciferol-treated and 50% of placebo-treated patients achieved AVF maturation (p=0.7). Baseline concentrations of serum 25(OH)D and 1,25(OH) 2 D were similar between patients who experienced AVF or AVG maturation and those who did not (p=0.22 and 0.59, respectively). Similarly, there was no relationship between AVF or AVG maturation and posttreatment serum 25(OH)D and 1,25(OH) 2 D concentration (p=0.24 and 0.51, respectively).
Following adjustment for age, diabetes and race, there was no association between AVF maturation and baseline, posttreatment or change in serum 25(OH)D concentrations (p=0.97, 0.54, 0.56, respectively), or serum 1,25(OH) 2 D concentrations (p=0.51, 0.61, 0.43, respectively). These findings were similar when including AVGs in the analysis.
DISCUSSION
We found that perioperative correction of 25(OH)D insufficiency and deficiency was achieved with high-dose cholecalciferol, but did not appear to have an association with AV access maturation among ESRD patients who received an AVF or AVG, although serum 25(OH)D concentrations normalized in 90% of cholecalciferol-treated subjects.
While no previous study has examined serum 25(OH) D concentration as a predictor of AV access maturation, previous work supports a role for vitamin D in the regulation of VSMC proliferation. VDRs are present in numerous tissues, including the endothelium and VSMCs, which also express 1-alpha-hydroxylase, the enzyme that converts 25(OH)D to 1,25(OH) 2 D (11, 31) .
Animal experiments suggest that vitamin D concentrations are associated with intimal proliferation, and that vitamin D inhibits VSMC proliferation (4, 32) . Gupta et al recently demonstrated that serum 25(OH)D concentration may affect the extent of resultant neointimal thickening in an atherosclerotic swine model following arterial injury (32) . Six months following percutaneous balloon angioplasty (PTA) to the coronary arteries, the percent area of arterial neointimal hyperplasia was significantly greater (p<0.05) among the group of animals fed a vitamin D-deficient high-cholesterol diet (72.5%±4.5%) compared with those fed a vitamin D-sufficient high-cholesterol diet (54.9%±3.7%). Proliferating cell nuclear antigen, a marker of SMC proliferation, was more abundant in cells within the balloon-injured arteries of vitamin D-deficient animals compared with vitamin D-sufficient animals, suggesting that vitamin D has an antiproliferative effect. Moreover, Gupta et al found that VDR expression was significantly downregulated and that TNF-alpha expression was increased in proliferating VSMCs within neointimal lesions following vessel injury. They also showed that VDR expression in cultured VSMCs increased with calcitriol stimulation, yet significantly decreased with TNF-alpha treatment, suggesting that the presence of inflammation following vessel injury may downregulate VSMC VDR and contribute to VSMC proliferation and restenosis.
In the mouse aortic allograft, a model of immunemediated vascular intimal hyperplasia, VDR expression is present in aortic cells (4). Adorini et al reported that mice receiving aortic allografts that were treated with vitamin D3 analogue supplementation had significantly less intimal cell proliferation within allogeneic aortic segments 60 days after transplant, compared with vehicle mice.
While these findings suggest the potential benefit of vitamin D on the attenuation of VSMC proliferation and neointimal hyperplasia following injury from percutaneous angioplasty, they may be relevant to chronic kidney disease (CKD) and ESRD patients undergoing AV access creation. First, our group and others (33, 34) have shown that venous intimal hyperplasia preexists in latestage non-dialysis CKD patients, a population with a high prevalence of vitamin D insufficiency and deficiency (35) . While preexisting intimal hyperplasia has not been linked to AV access failure, it remains unclear whether these lesions progress following AV access creation. Second, it is estimated that approximately 30% of patients with newly created AVF undergo AVF PTA to promote maturation (36), or develop stenosis in vessel segments typically manipulated during surgical AVF creation (37) . Therefore, a cost-effective intervention that could potentially reduce the magnitude of subsequent AVF restenosis may have significant impact.
Successful AVF maturation is also dependent upon compensatory dilation of the inflow artery and adequate dilation and blood flow to the outflow vein (38) (39) (40) . Data suggest that vasoactive function is influenced by vitamin D sufficiency. Tare et al (41) examined the effect of vitamin D insufficiency on endothelial and smooth muscle function in the arteries of offspring of vitamin D-deficient rats. The vitamin D-deficient rat offspring had only half of the endothelium-derived nitric oxide-evoked arterial dilation and virtually no endothelium-derived hyperpolarizing factor compared with control rats, reflecting a pronounced impairment in arterial relaxation. In accordance with these findings are the results showing that Vitamin D and dialysis access maturation vitamin D therapy increases flow-mediated dilation in adult humans (42) .
Other favorable effects of vitamin D on AVF maturation may include suppression of matrix metalloproteinases (MMP) and a reduction in thrombotic factors. MMPs are linked to the development of intimal hyperplasia (43, 44) and identified in vein segments of failed AVF (45) . Greater local vitamin D activity may reduce intimal hyperplasia by lessening the effect of MMP remodeling within the vein, as treatment with vitamin D3 is shown to suppress MMP-2 and -3 in vitro, and circulating serum 25(OH)D is inversely associated with plasma MMP-9 concentration in ESRD patients (5, 46) .
Reports also suggest that VDR activation has antithrombotic effects. Plasminogen activator inhibitor type 1 (PAI-1), a procoagulant, proinflammatory protein, is reduced in vitro by paricalcitol, a vitamin D analogue (7, 8) .
It is also noted that VDR activation in vivo decreases platelet aggregation via regulation of antithrombin gene expression in the liver (47) . When evaluated in humans, vitamin D appears to play a role in coagulation. Cancer patients treated with high-dose 1,25(OH) 2 D had significantly fewer venous and arterial thrombotic events than did those treated with standard dose 1,25(OH) 2 D (48).
Our study has some limitations worth mentioning. Although this was a pilot study, a sample size of 50 patients (25 per group) was determined to achieve power of 0.8 when estimating that 52% of placebo-treated patients versus 88% of cholecalciferol-treated patients would experience AVF maturation. Instead, we found that 54% of placebo-treated patients versus 45% of cholecalciferoltreated patients were successfully using their AVF or AVG at 6 months. This finding suggests that any advantage that vitamin D confers is much lower than our original estimate, in which case our study was underpowered to detect it. It is possible that AV access outcome was influenced by variability in surgical technical expertise; however, we attempted to address this by limiting the vascular surgeons performing AV access procedures to two highly experienced individuals (W.M., G.S.), and there was no difference in AV access outcomes. In addition, postoperative AV access cannulation and vascular access management may have varied between intervention and control subjects. We attempted to limit variation by recruiting patients from dialysis units with a uniform cannulation protocol and dialysis providers. Finally, we may have failed to see a benefit with cholecalciferol on AVF maturation because longer presurgical vitamin D sufficiency (>6 months, for example) may be required.
We found that high-dose vitamin D3 therapy in patients with ESRD undergoing AVF creation successfully corrected vitamin D insufficiency and deficiency, but did not appear to improve AVF maturation rates compared to a cohort of matched controls in our pilot, double-blind, randomized, controlled study. Conclusive results will likely require a larger patient sample to achieve adequate effect size. Further, the role for vitamin D in AV access maturation may need to be explored in larger studies with extended preoperative supplementation or in certain subpopulations at high risk for AVF failure.
